Report
EUR 13.59 For Business Accounts Only

Despite a better risk assessment and improving to Neutral, 3SBIO INCO. remains under pressure

3SBIO INCO. (HK), a company active in the Biotechnology industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date August 16, 2019, the closing price was HKD 12.00 and its target price was estimated at HKD 9.95.
Underlying
3SBio (P Chip)

3SBio and its subsidiaries are engaged in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China. Co. manufactures and distributes five types of biopharmaceutical products: EPIAO that is used to stimulate the production of red blood cells in patients with anemia; TPIAO for the treatment of chemotherapy-induced thrombocytopenia; Intefen for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; Inleusin for the treatment of renal cell carcinoma, metastatic melanoma, thoratic fluid build-up caused by cancer and tuberculosis; and iron sucrose supplement designed to treat anemia.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch